Order Article Reprints

Ding L, Nuersulitan R, Wang J, Chen H, Zhuo M. Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. Current Oncology. 2026; 33(5):258. https://doi.org/10.3390/curroncol33050258

Ding, Lu, Reyizha Nuersulitan, Jingjing Wang, Hanxiao Chen, and Minglei Zhuo. 2026. "Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression" Current Oncology 33, no. 5: 258. https://doi.org/10.3390/curroncol33050258

Ding, L., Nuersulitan, R., Wang, J., Chen, H., & Zhuo, M. (2026). Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. Current Oncology, 33(5), 258. https://doi.org/10.3390/curroncol33050258